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Antimicrobial peptides (AMPs), also known as host defense peptides, are short and
generally positively charged peptides found in a wide variety of life forms from
microorganisms to humans. Most AMPs have the ability to kill microbial pathogens
directly, whereas others act indirectly by modulating the host defense systems. Against
a background of rapidly increasing resistance development to conventional antibiotics
all over the world, efforts to bring AMPs into clinical use are accelerating. Several AMPs
are currently being evaluated in clinical trials as novel anti-infectives, but also as new
pharmacological agents to modulate the immune response, promote wound healing, and
prevent post-surgical adhesions. In this review, we provide an overview of the biological
role, classification, andmode of action of AMPs, discuss the opportunities and challenges
to develop these peptides for clinical applications, and review the innovative formulation
strategies for application of AMPs.
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INTRODUCTION
The rapidly increasing resistance toward conventional antibiotics suggests that, without urgent
action, we are heading for a “post-antibiotic era,” in which the previously effective therapeutic
strategies are no longer relevant. Due to the limited number of available antibiotics, and the
similarities in their activity spectrum as well as mode of action, intensive nonclinical and clinical
research is now invested into identification of new and non-conventional anti-infective therapies,
including adjunctive or preventive approaches such as antibodies targeting a virulence factor,
probiotics, and vaccines (Czaplewski et al., 2016). Interestingly, the antimicrobial peptides (AMPs)
have rapidly captured attention as novel drug candidates (Figure 1). AMPs have been found
virtually in all organisms and they display remarkable structural and functional diversity. Besides
direct antimicrobial activity, AMPs carry immunomodulatory properties (Fjell et al., 2012), which
make them especially interesting compounds for the development of novel therapeutics. There are
encouraging examples of AMPs already introduced into the market, and many AMPs are currently
being tested in clinical trials (Fox, 2013), which provide a reason for optimism for introduction of
novel AMP-based drugs in several indication areas.
With no attempt to provide a comprehensive overview with regards to all types of AMPs
identified from different sources, this review focuses on applied therapeutic aspects with the
emphasis of AMPs being evaluated as potential pharmacological agents.
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FIGURE 1 | Published research on AMPs identified from 2004 until
September 2016. Article counts were carried out after searching in PubMed
using the following key words: antimicrobial peptides, AMPs, and/or host
defense peptides. The search results demonstrate that in the last decade the
AMP research field has progressively expanded as represented by the
continuous increase in the number of articles. Q, quarter.
BIOLOGICAL ROLE AND CLASSIFICATION
OF AMPS
AMPs are evolutionary conserved in the genome and produced
by all life forms, from prokaryotes to humans (Hancock, 2000).
In higher organisms, AMPs constitute important components
of the innate immunity, protecting the host against infections.
In contrast, bacteria produce AMPs in order to kill other
bacteria competing for the same ecological niche (Hassan
et al., 2012). Many AMPs exhibit an extraordinarily broad
range of antimicrobial activity covering both Gram-positive
and Gram-negative bacteria as well as fungi, viruses, and
unicellular protozoa (Hancock and Diamond, 2000; Reddy et al.,
2004; Marr et al., 2006). Besides having a direct antimicrobial
activity, several AMPs display ability to modulate the innate
immune responses of the host and thereby indirectly promote
pathogen clearance (Hancock and Sahl, 2006; Yeung et al., 2011).
The widespread distribution and abundance of AMPs in all
multicellular organisms underscores their critical role in innate
immunity (Zasloff, 2002; Hancock et al., 2012). Their importance
is further demonstrated by the increased infection susceptibility
of mice genetically modified to lack the gene encoding for the
mouse analog of the humanAMP LL-37 (Nizet et al., 2001) and of
humans with diseases associated with reduced AMP production
such as atopic dermatitis (Ong et al., 2002).
AMPs in nature are produced either by ribosomal translation
of mRNA or by nonribosomal peptide synthesis (Hancock and
Chapple, 1999). While nonribosomally synthesized peptides are
mainly produced by bacteria, the ribosomally synthesized AMPs
are genetically encoded and produced by all species of life,
bacteria included (Hancock and Chapple, 1999). Compared to
peptides of nonribosomal origin that have been known for
several decades and whereof many are used as antibiotics (e.g.,
polymyxins and gramicidin S), the ribosomally synthesized
AMPs have more recently been recognized for their critical role
FIGURE 2 | Peptides representing the three main categories of the
secondary structures of AMPs. LL-37 and human lactoferricin represent
α-helical peptides, human β-defensin 1 represents β-sheet peptides, and
indolocidin represents extended/random-coil structures. Structures are from
Protein Data Bank in Europe (PDB id codes 2k6o, 1z6v, 1kj5, and 1g89).
in innate immunity and for their therapeutic potential (Hancock
and Chapple, 1999; Hancock, 2000).
In mammals, AMPs are found primarily within granules of
neutrophils and in secretions from epithelial cells covering skin
and mucosal surfaces (Boman, 1995; Hancock and Chapple,
1999). In many cases, AMPs are encoded in clusters in
the genome and co-expressed, resulting in multiple AMPs
accumulating at a single site (Lai and Gallo, 2009). Notably, many
AMPs are produced as inactive precursors requiring proteolytic
cleavage to become active (Bals, 2000). Their regulation is
therefore not only dependent on their own expression but also on
the abundance of appropriate proteases (Lai and Gallo, 2009). In
multicellular organisms, someAMPs are constitutively expressed,
stored at high concentrations as inactive precursors in granules
and released locally at infection and inflammation sites, whereas
the expression of others is induced in response to pathogen-
associated molecular patterns (PAMPs) or cytokines (Hancock
and Diamond, 2000; Lai and Gallo, 2009).
Several databases exist for natural AMPs, today covering more
than 2000 peptides (Wang, 2015). Most AMPs are relatively
short, commonly consisting of 10–50 amino acids, display an
overall positive charge ranging from +2 to +11, and contain a
substantial proportion (typically 50%) of hydrophobic residues
(Yeaman and Yount, 2003; Hancock and Sahl, 2006; Pasupuleti
et al., 2012). AMPs are commonly classified based on their
secondary structure into α-helical, β-sheet, or peptides with
extended/random-coil structure (Takahashi et al., 2010; Nguyen
et al., 2011; Pasupuleti et al., 2012), with most AMPs belonging
to the first two categories (Figure 2). α-helical peptides are often
unstructured in aqueous solution, but adopt an amphipathic
helical structure in contact with a biological membrane (Yeaman
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and Yount, 2003; Pasupuleti et al., 2012). Two of the most
studied peptides in this group are: (i) LL-37 (Epand and
Vogel, 1999; Pasupuleti et al., 2012), which is produced
as an inactive precursor in the 18-kDa human cathelicidin
antimicrobial protein (hCAP18), present in neutrophils and
epithelial cells (Lai and Gallo, 2009), and (ii) human lactoferricin,
which is derived by proteolytic cleavage of the antimicrobial
and immunomodulatory iron-binding glycoprotein lactoferrin,
present in milk and exocrine secretions (Hunter et al., 2005;
Legrand et al., 2005). β-sheet peptides are stabilized by disulphide
bonds (Powers and Hancock, 2003; Yount et al., 2006) and
are organized to create an amphipathic molecule (Yeaman
and Yount, 2003). Due to their rigid structure, the β-sheet
peptides are more ordered in aqueous solution and do not
undergo as drastic conformational change as helical peptides
upon membrane interaction (Yeaman and Yount, 2003). The
best-studied β-sheet peptides are the defensins—a large group of
AMPs, which are produced as inactive precursors in neutrophils,
macrophages, and epithelial cells (Lai and Gallo, 2009; Pasupuleti
et al., 2012). A small portion of the natural AMPs belong to
the third class of extended/random-coil peptides which lack
secondary structure and often contain a high content of arginine,
proline, tryptophan, and/or histidine residues (Takahashi et al.,
2010; Nguyen et al., 2011). Similarly to other AMPs, many of
the extended peptides fold into amphipathic structures after
contact with a membrane (Nguyen et al., 2011). One of the best
studied peptides in this group is indolicidin, produced by bovine
leukocytes (Powers and Hancock, 2003).
MECHANISM OF ACTION OF AMPS
Interaction with Bacterial Membrane
Many AMPs display a direct and rapid antimicrobial activity
by causing disruption of the physical integrity of the microbial
membrane and/or by translocating across the membrane into the
cytoplasm of bacteria to act on intracellular targets (Hancock and
Sahl, 2006). It is widely accepted that membrane interaction is
a key factor for the direct antimicrobial activity of AMPs, both
when the membrane itself is targeted and when an intracellular
target must be reached by means of translocation (Jenssen et al.,
2006; Nguyen et al., 2011; Yeung et al., 2011; Malmsten, 2016).
Electrostatic forces between the cationic AMPs and the negatively
charged bacterial surface are critical determinants for this
interaction between peptides and microbial membrane (Yeaman
and Yount, 2003; Giuliani et al., 2007; Yeung et al., 2011; Ebenhan
et al., 2014). Bacteria are commonly divided into two families,
Gram-positive and Gram-negative, based on the differences
in cell envelope structure. In Gram-positive bacteria, the
cytoplasmic membrane is surrounded by a thick peptidoglycan
layer, whereas the cytoplasmic membrane of Gram-negative
bacteria is surrounded by a thin peptidoglycan layer as well as
an outer membrane (Lin and Weibel, 2016). The cytoplasmic
membranes of both Gram-positive and Gram-negative bacteria
are rich in the phospholipids phosphatidylglycerol, cardiolipin,
and phosphatidylserine, which have negatively charged head
groups, highly attractive for positively charged AMPs (Yeaman
and Yount, 2003; Ebenhan et al., 2014). The presence of
teichoic acids in the cell wall of Gram-positive bacteria and
lipopolysaccharides (LPS) in the outer membrane of Gram-
negative bacteria provide additional electronegative charge to the
bacterial surface (Lai and Gallo, 2009; Ebenhan et al., 2014).
The fundamental differences between microbial and
mammalian membranes protect mammalian cells against
AMPs and enable selective action of these peptides (Yeaman
and Yount, 2003). In contrast to bacteria, the cytoplasmic
membrane of mammalian cells is rich in the zwitterionic
phospholipids phosphatidylethanolamine, phosphatidylcholine,
and sphingomyelin, providing a membrane with a neutral
net charge (Yeaman and Yount, 2003; Ebenhan et al., 2014).
There is also an asymmetric distribution of phospholipids in
mammalian membranes, with the zwitterionic phospholipids
being present in the outer leaflet, while phospholipids with
negatively charged head groups, if present, are localized in
the inner leaflet facing the cytoplasm (Zasloff, 2002; Yeaman
and Yount, 2003; Lai and Gallo, 2009). Therefore, interactions
between AMPs and mammalian cell membrane occur mainly via
hydrophobic interactions, which are relatively weak compared
to the electrostatic interactions taking place between AMPs and
bacterial membranes. Furthermore, mammalian cell membranes,
unlike those of microbes, have a high content of cholesterol
(Yeaman and Yount, 2003; Lai and Gallo, 2009). The cholesterol
is proposed to reduce the activity of AMPs via stabilization
of the phospholipid bilayer (Zasloff, 2002). Notably, bacterial
cells typically have an inside-negative transmembrane potential
between −130 and −150 mV in contrast to mammalian cells,
where the potential ranges from −90 to −110 mV (Yeaman and
Yount, 2003; Matsuzaki, 2009; Ebenhan et al., 2014). A stronger
negative membrane potential in bacteria may also contribute
to selectivity of AMPs between bacterial vs. mammalian cells
(Yeaman and Yount, 2003).
Membrane Disruption and Intracellular
Targets in Bacterial Cells
In order to reach the cytoplasmic membrane of Gram-negative
bacteria, AMPs have to first translocate through the outer
membrane. This outer membrane constitutes a permeability
barrier for many macromolecules, partly due to the divalent
cations Ca2+ and Mg2+ that bind to the phosphate groups of
the inner core of LPS and thereby provide stabilization of the
outer leaflet (Clifton et al., 2015). AMPs are proposed to be
translocated through this outer membrane via so called self-
promoted uptake (Hancock, 1997; Hancock and Chapple, 1999;
Giuliani et al., 2007). This model suggests that, due to greater
affinity for the LPS, AMPs displace the divalent cations and
bind to the LPS. By being bulky, the AMPs then cause transient
cracks and permeabilize the outer membrane, thereby permitting
passage of the peptide itself across the membrane.
In contact with the cytoplasmic membrane, the AMPs form
an amphipathic secondary structure (if not already present)
essential for interaction with the cell membrane (Ebenhan et al.,
2014). The charged domains of the peptide allow for interaction
with the hydrophilic head groups of the phospholipids, while
the hydrophobic domains of the peptide interact with the
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hydrophobic core of the lipid bilayer, thereby driving the AMP
deeper into the membrane (Ebenhan et al., 2014). Several models
have been proposed describing the next events occurring at
the bacterial cytoplasmic membrane, which ultimately lead to
membrane permeabilization (Figure 3; Brogden, 2005; Toke,
2005; Nguyen et al., 2011). According to the “barrel-stave
model,” the peptides insert perpendicularly into the bilayer
while recruitment of additional peptides subsequently results in
formation of a peptide-lined transmembrane pore. In this pore,
the peptides are aligned with the hydrophobic side facing the
lipid core of the membrane and the hydrophilic regions facing
the interior region of the pore. According to the “toroidal-pore
model,” insertion of peptides forces the phospholipid to bend
continuously from one leaflet to the other, resulting in a pore
lined by both peptides and the head groups of the phospholipids.
Finally, in the “carpet model,” accumulation of peptides on the
membrane surface causes tension in the bilayer that ultimately
leads to disruption of the membrane and formation of micelles.
Membrane permeabilization by AMPs is suggested to
initially lead to leakage of ions and metabolites, depolarization
of the transmembrane potential with subsequent membrane
dysfunction (e.g., impaired osmotic regulation and inhibition of
respiration), and ultimately, membrane rupture and rapid lysis of
microbial cells (Yeaman and Yount, 2003; Brogden, 2005; Eckert,
2011).
Besides leading to membrane dysfunction and disruption,
membrane permeabilization is important for translocation of
certain AMPs into the cytoplasm, where they target key cellular
processes including DNA/RNA and protein synthesis, protein
folding, enzymatic activity, and/or cell wall synthesis (Figure 3;
Yeaman and Yount, 2003; Brogden, 2005; Yount et al., 2006;
Nguyen et al., 2011).
Notably, it is suggested that bacterial death caused by AMPs
could be a result of multiple and complementary actions, referred
to as multi-hit mechanism. This strategy helps to increase
the efficiency of AMPs and to evade resistance development
(Zhang et al., 2000; Yeaman and Yount, 2003; Peschel and
Sahl, 2006; Nguyen et al., 2011). It is likely that the mode
of action of individual AMPs varies depending on parameters
such as peptide concentration, target bacterial species, as
well as tissue localization and growth phase of the bacteria
(Yeaman and Yount, 2003; Jenssen et al., 2006). Importantly,
regardless of the exact mode of action and target site, the
antibacterial activity of AMPs is dependent on the interaction
with microbial membrane (Jenssen et al., 2006; Yeung et al.,
2011).
Interestingly, the membrane-destabilizing activity of
AMPs is also utilized in so called Artilysins, which have
recently shown potential to effectively target resistant and
persistent Gram-negative infections. Artilysins are engineered
fusions of bacteriophage-encoded endolysins, which degrade
peptidoglycans of the bacterial cells wall, with specific AMPs,
which facilitate the transduction of the endolysin through the
protective outer membrane of Gram-negative pathogens to reach
its substrate (Briers et al., 2014a,b; Briers and Lavigne, 2015;
Defraine et al., 2016).
FIGURE 3 | Schematic illustration of bacterial killing mechanisms by AMPs.
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Immunomodulatory Activities
Recently published analysis of the available patent information
referring to the therapeutic use of AMPs covering the period
from 2003 to 2015 concluded that most of the claimed
AMPs were characterized not only as potent antibiotics, but
also as effective modulators of inflammation or neutralizers
of pathogenic toxins (Kosikowska and Lesner, 2016). The
broad range of immunomodulatory activities exerted by AMPs
include stimulation of chemotaxis, modulation of immune cell
differentiation and initiation of adaptive immunity, together
contributing to the bacterial clearance of the host (Figure 4). The
immunomodulatory activities further include suppression of toll-
like receptors (TLR)- and/or cytokine-mediated production of
proinflammatory cytokines and anti-endotoxin activity, together
preventing excessive and harmful proinflammatory responses
including sepsis (Håversen et al., 2002; Davidson et al., 2004;
Mookherjee et al., 2006; Lai and Gallo, 2009; van der Does
et al., 2010; Yeung et al., 2011; Figure 4). As an example, LL-
37 and bovine lactoferricin have been reported to inhibit the
LPS (TLR4)-induced secretion of TNF-α and IL-6, respectively,
in THP-1 cells and, in addition, LL-37 suppresses the LTA
(TLR2)- and LPS (TLR4)-induced production of TNF-α, IL-
1β, IL-6, and IL-8 in primary monocytes (Mattsby-Baltzer
et al., 1996; Mookherjee et al., 2006). Several mechanisms have
been proposed to explain these immunomodulatory actions
of AMPs on mammalian cells (Lai and Gallo, 2009). In the
“alternate ligand model,” the AMPs bind directly to specific cell
surface receptors thereby inducing receptor signaling. In the
“membrane disruption model,” the AMPs locally modify the part
of membrane that contains the receptor and thereby indirectly
alter the activation state and function of the receptor. In the
“trans-activationmodel,” the AMPs cause release of a membrane-
bound factor, which could then bind to its receptor (Lai and
Gallo, 2009). In addition, scavenging of the endotoxin LPS by
AMPs has been suggested, preventing LPS from binding the
TLR4 and triggering inflammation (Lai and Gallo, 2009).
POTENTIAL FOR DEVELOPMENT OF
BACTERIAL RESISTANCE TO AMPS
The widespread bacterial resistance development toward AMPs
has generally been considered to be unlikely due to the AMPs’
mechanism of action involving attacking multiple low-affinity
targets rather than one defined, high-affinity target characteristic
for conventional antibiotics, which makes it more difficult for
FIGURE 4 | Schematic illustration of immunomodulatory activities of AMPs. Pathogen recognition via pathogen recognition receptors (PRRs), such as TLRs,
by epithelial cells, macrophages, and dendritic cells, leads to killing via phagocytosis as well as release of proinflammatory cytokines and chemokines by these cells,
that subsequently stimulates the recruitment of additional immune cells to the site of infection. In addition, pathogen insult will lead to maturation of dendritic cells and
subsequent initiation of adaptive immunity. AMPs indirectly promote pathogen clearance by stimulating chemotaxis and immune cell differentiation, while also
preventing harmful inflammation and sepsis by inhibition of proinflammatory cytokine release and direct scavenging of bacterial endotoxins such as LPS. Up- or
down-regulation of responses by AMPs is indicated by green arrows.
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target microbes to defend themselves by a single resistance
mechanism (Peschel and Sahl, 2006; Lai and Gallo, 2009; Fjell
et al., 2012). In particular, given that the bacterial cell membrane
is the primary target of AMPs, it is challenging for microbes to
preserve the cell membrane functional and structural integrity
while at the same time avoiding the membrane-disrupting
activity of AMPs (Lai and Gallo, 2009). However, considerable
experimental data has recently emerged describing mechanisms
by which bacteria may develop resistance toward AMPs under
selection pressure in vitro (Pränting et al., 2008; Lofton
et al., 2013), warranting further investigations of the potential
risks of bacterial AMP resistance. The detailed discussion on
the underlying mechanisms and consequences of microbial
resistance to AMPs is beyond the scope of this review, and the
reader is referred to the excellent recent review by Andersson
et al. (2016).
AMPS AS THERAPEUTIC AGENTS
The rapid bactericidal activity of AMPs makes them promising
candidates for therapeutic anti-infectives. Furthermore, several
AMPs have a broad range of action, which is an advantage in
certain therapeutic areas, such as complicated skin and soft tissue
infections, where a rapidly increasing incidence of polymicrobial
infections involving both Gram-positive and Gram-negative
organisms has been reported over the last decade (Dryden, 2010).
To date, only a few AMPs are approved for clinical use, with
polymyxins, introduced already in the 1950s, being the most
well characterized (Falagas and Kasiakou, 2005; Zavascki et al.,
2007; Landman et al., 2008). Polymyxins are last-resort drugs
for intravenous treatment of drug-resistant infections caused by
Gram-negative pathogens, but they are also applied as topical
formulations in the prevention and treatment of local infections
(Zavascki et al., 2007).
There are numerous AMPs currently under clinical
development for the treatment against various bacterial
pathogens (Table 1) with pexiganan and omiganan, derived from
animal immune components, and synthetic LTX-109, being the
most well described. Pexiganan, a 22-amino-acid membrane
disruptor analog of the Xenopus peptide magainin, has been
evaluated as a topical cream for treating bacterial infections
associated with diabetic foot ulcers in two phase III clinical
trials (Clinical trial identifiers: NCT00563394, NCT00563433)
(Lamb and Wiseman, 1998; Lipsky et al., 2008), and additional
clinical trials are currently ongoing. Omiganan is a derivative
of indolicidin, which was isolated from bovine neutrophils, and
this AMP has been assessed as a topical gel in clinical trials for
catheter infections (NCT00231153) and rosacea (NCT01784133).
LTX-109 is a synthetic antimicrobial peptidomimetic, which has
been to date evaluated for local application in uncomplicated
Gram-positive skin infections (NCT01223222), impetigo
(NCT01803035), and in subjects nasally colonized with S.
aureus (NCT01158235) (Nilsson et al., 2015). While most of the
AMPs, including the above mentioned pexiganan, omiganan,
TABLE 1 | Selected AMPs in clinical phase of development.
AMP Description Phase Indication Administration Clinical trial identifier
if available
Pexiganan
(MSI-78)
Analog of magainin (skin
of African clawed frog)
Phase III Infected diabetic foot ulcers Topical cream NCT00563394,
NCT00563433
Omiganan Derived from indolicidin
(bovine)
Phase II/III Catheter infections and rosacea Topical gel NCT00231153,
NCT01784133
Lytixar
(LTX-109)
Synthetic antimicrobial
peptidomimetic
Phase I/II Uncomplicated Gram-positive skin infections,
impetigo, and nasal colonization with S.
aureus
Topical hydrogel NCT01223222,
NCT01803035,
NCT01158235
hLF1-11 Derived from lactoferricin
(human)
Phase I/II Bacteraemia and fungal infections in
immunocompromized haematopoetic stem
cell transplant recipients
Intravenous treatment (in saline) NCT00509938
Novexatin
(NP-213)
Derived from defensins
(human)
Phase II Onychomycosis (fungal nail infection) Topical brush-on-treatment
CZEN-
002
Dimeric octamer derived
from α-MSH (human)
Phase IIb Vaginal candidiasis Vaginal gel
LL-37 LL-37 (human) Phase I/II Hard-to-heal venous leg ulcers Polyvinyl alcohol-based solution
for administration in the wound
bed
PXL01 Derived from lactoferricin
(human)
Phase II Prevention of post-surgical adhesion
formation in hand surgery
Hyaluronic acid-based hydrogel
for administration at the surgical
site
NCT01022242
Iseganan
(IB-367)
Derived from protegrin 1
(porcine leukocytes)
Phase III Oral mucositis in patients receiving
radiotherapy for head and neck malignancy
Oral solution NCT00022373
PAC-113 Derived from histatin 3
(human saliva)
Phase II Oral candidiasis in HIV seropositive patients Mouthrinse NCT00659971
α-MSH, α-melanocyte-stimulating hormone.
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and LTX-109, are developed for local application, there are
a few AMPs aimed for systemic administration. hLF1-11 is a
cationic fragment comprising N-terminal amino acids 1-11
of human lactoferricin, and this peptide is developed for
the intravenous treatment of life-threatening bacterial and
fungal infections in immunocompromised stem cell transplant
recipients (NCT00509938) (Velden et al., 2009). In addition
to hLF1-11, there are several other AMPs being developed for
treatment of fungal infections. For example, novexatin, a cyclic
and highly cationic peptide based on human α- and β-defensins,
is targeting stubborn fungal infections in toenails (Fox, 2013)
while CZEN-002, a dimeric peptide sequentially derived from
α-melanocyte-stimulating hormone (α-MSH), is targeting
vaginal candidiasis (Fjell et al., 2012).
Notably, several AMPs are currently under clinical
development for therapeutic indications other than
antimicrobials or antifungal agents. One of the most well-
known of these peptides is LL-37, which has recently been
evaluated in a phase I/II clinical trial as a local treatment to
enhance healing of venous leg ulcers (Grönberg et al., 2014).
The mechanisms by which LL-37 promotes wound healing are
not fully understood, but are likely to involve several wound
repair components such as re-epithelialization, angiogenesis,
and inflammation. Reepithelialization is likely stimulated via
chemoattractant effects of LL-37 on epithelial cells (Shaykhiev
et al., 2005; Tokumaru et al., 2005) while vascularization is
thought to be regulated by LL-37 stimulating endothelial tube
formation and production of angiogenic factors (Lee et al.,
2008; Rodríguez-Martinez et al., 2008). LL-37 exerts also
chemoattractant effect on inflammatory cells (Chertov et al.,
1996) and regulates secretion of proinflammatory cytokines
(Scott et al., 2002; Niyonsaba et al., 2005; Mookherjee et al.,
2006). Another AMP currently in clinical development for its
properties other than anti-infection is PXL01. PXL01, which
similarly to hLF1-11 is derived from human lactoferricin, has
been evaluated in a hyaluronic acid-based gel formulation in a
phase II clinical trial for prevention of post-surgical adhesion
formation in connection to hand surgery (NCT01022242)
(Wiig et al., 2014). PXL01 exhibits an inhibitory effect on the
most important hallmarks of adhesion formation by repressing
secretion of proinflammatory cytokines and promoting
fibrinolysis (Nilsson et al., 2009). In addition, recent studies have
shown that PXL01 regulates the production of the mucinous
glycoprotein lubricin (Taguchi et al., 2009; Hayashi et al., 2013) in
connection to surgery, which provides an additional mechanism
to contribute to its adhesion-preventive properties (Edsfeldt
et al., 2016).
Aside from direct administration of AMPs, there are several
attempts ongoing to use agents to increase the endogenous
production of AMPs by the body in order to boost the innate
immune responses and thereby combat infections. As one
example, vitamin D3 has been shown to directly modulate
expression of several AMPs (Wang et al., 2004; Weber et al.,
2005) and vitamin D supplements are now evaluated for their
applicability for the treatment for bacterial infections in several
ongoing trials (Yamshchikov et al., 2009).
CHALLENGES TO DEVELOP AMPS FOR
CLINICAL APPLICATIONS
In spite of large number of AMPs going through clinical
development, there is still a considerable discrepancy between
the list of AMPs claimed as potent drug candidates in the
patents or related scientific articles and the real outcomes of
the clinical trials (Kosikowska and Lesner, 2016). Below, some
of the technical, regulatory, and commercial challenges to bring
AMP-based drugs into the clinical development are highlighted.
The design and optimization of therapeutic AMPs for
treatment of infections usually starts with in vitro screening
of the constellation of known or predicted peptide sequences
for their antibacterial and/or antifungal properties using
standard minimal inhibitory concentration (MIC) or minimal
microbicidal concentration (MMC) assays (Fjell et al., 2012).
However, the antimicrobial and antifungal activity of the AMPs
is highly sensitive to environmental conditions, which results
in discrepancies between in vitro vs. in vivo efficacy and
makes the accurate prediction of anti-infection properties in
clinical situation very difficult. Numerous reports describe AMPs
with the desired in vivo antimicrobial effect demonstrated in
relevant experimental animal models, while peptides appear
to be inactive, or minimally active, when their efficacy was
evaluated in MIC/MMC assays in the presence of physiologic
salt concentrations and/or serum (Goldman et al., 1997; Bals
et al., 1998; Ciornei et al., 2005; Dorschner et al., 2006;
Chennupati et al., 2009; Björn et al., 2012; Myhrman et al.,
2013; Rivas-Santiago et al., 2013; Maiti et al., 2014). Moreover,
a number of naturally occurring AMPs are present in their native
environment at concentrations, which do not kill bacteria in vitro
(Dorschner et al., 2001). Several possible explanations for this
apparent paradox have been put forward. It has been suggested
that bacterial susceptibility to AMPs may be significantly higher
in the mammalian ionic environment, which is not replicated in
MIC/MMC assays. For example, when grown in the presence of
carbonate, a ubiquitous molecule in many microenvironments
of the body, both Gram-positive and Gram-negative bacteria
show dramatically increased AMP sensitivity (Dorschner et al.,
2006). It has also been proposed that the in vivo antibacterial
activity of some AMPs is mediated primarily through their
immunomodulatory effects rather than direct bacterial killing
(Hancock and Sahl, 2006). On the other hand, AMPs displaying
low MIC/MMC values in vitro may lack activity in vivo due to
their rapid proteolytic degradation and/or protein binding in
the body. In summary, the poor correlation between in vitro
antimicrobial activity of AMPs and their in vivo efficacy is one
of the technical obstacles, which has hampered the progression
of these drug candidates toward clinical development.
Low metabolic stability of AMPs, which is an inherent
risk of therapeutic peptides in general, is considered another
key factor limiting their clinical application. Peptide drugs
are generally characterized by low oral bioavailability due to
pre-systemic enzymatic degradation and poor penetration of
the intestinal mucosa, which makes their oral administration
usually not possible (Vlieghe et al., 2010). Furthermore, systemic
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administration of peptides by, e.g., intravenous injection, is
limited by a short half-life because of rapid degradation by
proteolytic enzymes in blood plasma and rapid removal from
the circulation by the liver (hepatic clearance) and kidneys (renal
clearance) (Vlieghe et al., 2010). Consequently, local application
of AMPs is the most common administration route including
delivery in dermal creams and emollients, administration at
the wound bed or the site of the surgery, mucosal application
as nasal spray and similar. However, even upon local delivery,
peptides are prone to degradation by tissue proteolytic enzymes.
To reduce the liability of degradation by peptidases/proteases,
cyclization of the AMPs, incorporation of D-amino acids and
non-natural amino-acid analogs, and peptide mimetics with
different backbone structures, are widely used (Fjell et al., 2012).
End-tagging by hydrophobic oligo amino acid stretches has also
been shown to diminish sensitivity of AMPs for proteolytic
degradation (Malmsten et al., 2011). Furthermore, blocking
N- or C-terminal ends of the AMPs by modifications such as
N-acetylation, N-pyroglutamate, or C-amidation is frequently
used to increase resistance toward peptidases (Brinckerhoff et al.,
1999; Rink et al., 2010).
The relatively high costs of goods sold (COGS) of AMPs,
which applies to peptide therapeutics in general, is considered
another limitation to hamper AMPs’ competitiveness compared
with small molecule drugs. It is generally estimated that the
production cost of a 5000 Da molecular mass peptide exceeds
the production cost of a 500 Da molecular mass small molecule
by more than 10-fold (Bray, 2003). Solid phase peptide synthesis
(SPPS), the most commonly used method for chemical synthesis
of therapeutic peptides (Amblard et al., 2006), is generally
considered as the most mature technology available, at least
for production of peptides with up to 50 amino acid residues
(Raibaut et al., 2015). Production systems for recombinant
peptides including bacteria, yeast, insect, and mammalian cells
are alternatives to chemical synthesis; however, they typically
require a long and expensive R&D phase and have limitations
in relation to ability to introduce modifications into the peptide
sequence. Although most of the AMPs, being relatively short,
are produced by chemical synthesis, several AMPs such as a
fungal defensin plectasin variant AP114 (formerly NZ2114), once
developed by Novozymes for treating Gram-positive bacterial
infections, and now owned by Adenium Biotech, are produced
using a recombinant route (Mygind et al., 2005).
Regulatory hurdles may also considerably delay the clinical
development of AMPs. Notably, some of the most well
characterized AMPs—omiganan and pexiganan—have during
their clinical testing run into regulatory barriers (Fox, 2013).
Importantly, recognizing the decline in the approval of new
anti-infectious agents, in combination with the alarming rise
in resistance toward conventional antibiotics, has resulted in
recent initiatives at governmental level as well as by regulatory
authorities to facilitate development of novel anti-infectives such
as additional years of market exclusivity and more flexibility
with respect to clinical trial design (Fox, 2013). Interestingly,
from a regulatory perspective, the peptide therapeutics tend to
be considered as being a “mix” of both classical small molecules
and biologics, since they are synthetic molecules but based
on or having the same mechanism of action as endogenous
proteins/peptides. The balance in this “mix” may differ in
different territories, which makes the regulatory landscape,
especially in relation to chemistry, manufacturing, and controls
(CMC), more complex.
In relation to the safety profile of AMPs, only very few
publications describing standardized toxicology data sets for
AMPs are available (Björn et al., 2015). Moreover, given the
low number of AMPs in clinical practice, the characterization
of adverse effects in connection to administration in humans is
limited with the exception of polymyxins, where systematicmeta-
analysis of safety is available and high incidence of nephrotoxicity
and neurotoxicity associated with intravenous administration
has been reported (Falagas and Kasiakou, 2006). In general,
peptide therapeutics are considered to have advantages from
the safety perspective compared to small molecule drugs since
their degradation products are natural amino acids and, because
of their short half-life, few peptides accumulate in tissues.
Altogether, this reduces the safety risk and risk of complications
caused by metabolites (Vlieghe et al., 2010). Notably, therapeutic
peptides, even synthetic ones, are generally less immunogenic
than recombinant proteins and antibodies (McGregor, 2008).
Finally, local administration, which is the most common delivery
route for AMPs, further reduces the risk for any systemic
toxicology concerns.
INNOVATIVE FORMULATION STRATEGIES
FOR AMPS
The stability, safety, and efficacy of AMPs can be further
improved through innovative formulation strategies and design
of drug delivery systems. Until now, only limited attention has
been paid to this area although formulation offers the possibility
to target the delivery of AMPs to a specific site with controlled
release over time, thus minimizing side-effects and increasing
efficacy (Eckert, 2011). Particularly interesting in this context is
the use of nanocarriers, which have unique advantages due to
their large surface area for adsorption/encapsulation of AMPs
and prevention of self-aggregation of the peptides. Furthermore,
nanostructured materials enable the design of formulations for
local delivery to specific tissues and, by controlling degradation
of the carrier, allow time-controlled release of the peptides, in
addition to improving metabolic as well as chemical stability of
the AMPs (Zhang et al., 2010; Witting et al., 2015; Sandreschi
et al., 2016). Importantly, nanocarriers can be prepared from
biocompatible and biodegradable materials such as lipids (e.g.,
phospholipids, triglycerides, cholesterol, and monoolein) and
polymers [e.g., cellulose, chitosan, hyaluronic acid, poly lactic-co-
glycolic acid (PLGA), and poly lactic acid (PLA)].
Several types of nanocarriers have been evaluated for delivery
of AMPs with promising results. Hyaluronic acid nanogels
were recently shown to successfully encapsulate the LL-37
analog LLKKK18 and enhance the killing of mycobacteria
compared with the peptide alone both in vitro and in vivo
(Silva et al., 2016), demonstrating a potential for treatment of
tuberculosis. Importantly, the hyaluronic acid nanogels were
also able to stabilize the peptide against proteolytic degradation
and reduce the toxicity against host cells (Silva et al., 2016).
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PLGA nanoparticles have also shown potential in pulmonary
delivery of cationic AMPs for the treatment of cystic fibrosis,
where transport through the mucus layer and eradication of
Pseudomonas aeruginosa biofilm in vitro could be enhanced
by surface modification of the particles (d’Angelo et al.,
2015). Mesoporous silica nanoparticles (MSN) exhibit several
advantageous characteristics for encapsulation of AMPs due to
their well-defined large surface area pores and the possibility
to modify the surface properties, allowing fine-tuning of the
release pattern (Vallet-Regí et al., 2007). It has been reported
that the MSN surface properties and porosity influence the
distribution of LL-37 in/at the surface of the particles, which
in turn has a pronounced effect on the membrane adsorption,
antimicrobial effect, and toxicity against eukaryotic cells of LL-
37 as well as the ability of the particles to protect the peptide
from proteolytic degradation (Braun et al., 2016). Furthermore,
controlled-release of LL-37 from MSNs has been demonstrated
through incorporation into mesoporous silica membranes that
offers opportunities as surface coatings for implants (Izquierdo-
Barba et al., 2009). Recently, liquid crystalline lipid nanoparticles
and lipid nanocapsules have been investigated for encapsulation
of several cationic AMPs varying in biophysical properties, with
high loading efficacy and sustained or improved antimicrobial
effect observed for many of these systems, suggesting potential
for drug delivery (Boge et al., 2016; Umerska et al., 2016b).
Notably, in addition to stabilizing the AMP and targeting delivery
and release, nanocarrier material can have antimicrobial function
on its own, thereby boosting the effect of the AMP (Malmsten,
2011; Umerska et al., 2016a).
To this date, nanoformulations as delivery systems for AMPs
have only been evaluated in vitro and in experimental animal
models, but intense development is now ongoing in relation to
up-scaling and quality assurance of nanocarriers to bring these
products into clinical phases.
CONCLUSIONS
Overall, AMPs offer promising alternatives to standard
therapies as anti-infectives and immunomodulatory agents
with mechanisms of action which are less prone to resistance
induction compared to conventional antibiotics. Although
challenges in translating nonclinical candidate AMPs into
successful clinical products are well recognized, the discovery
and commercial development of next-generation therapeutic
peptides and peptide mimetics is predicted to be accelerated by
recent advances in overall understanding of their mechanism
of action, resistance patterns, and smart formulation strategies.
With several AMPs currently undergoing late stage clinical
development in different therapeutic areas, the next years hold
a promise to confirm the therapeutic benefit of these novel
candidates and lead to market authorization of several new
AMP-based drugs.
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